34 results about "Basal ganglia" patented technology

The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding glutamic acid decarboxylase (GAD) to cells in the subthalmic nucleus of the basal ganglia, mesaphilia and thalamus.

The invention provides a deep brain stimulation FPGA experimental platform of a basal ganglia and thalamencephalon network for the parkinson's disease. The experimental platform comprises an FPGA development board and an upper computer, which are connected with each other; the FPGA development board is used for realizing a basal ganglia and thalamencephalonneuron network model and a deep brain stimulation controller; the upper computer is used for designing an upper computer software interface and being communicated with the FPGA development board. The experimental platform has the benefits that as an animal-free experiment means of a biological neural network, and on the basis of the high-speed computation FPGA neuron network, the experimental platform realizes the modeling of the neuron network of a complex parkinson's disease focus area, and the neuron network model can be consistent with real biological neuron on a time scale. The platform provides a visual research platform, closer to the real neuron network, for researching the discharging mechanism of the parkinson's disease and the abnormal discharging mode of the basal ganglia and thalamencephalonneuron network controlled by deep brain stimulation, and has a significant practical value in researching the treatment of the parkinson's disease.

Metabolites and signatures (panels) of metabolites are applicable as biomarkers in clinical diagnosis, in particular for neonatal encephalopathy. They are useful tools in differential clinical diagnosis for early detection of brain injury, determination of brain areas affected by the insults and prediction of adverse neurological outcome and may also be applied in diagnosing disease progression and treatment effect. An in vitro method for predicting the likelihood of neonatal encephalopathy of distinct brain areas, identification of affected brain area(s) of neonatal encephalopathy and risk of brain damage and prognosis and neurological outcome due to identification of the type and extent of damage of distinct brain tissues, in particular of hippocampus and / or basal ganglia, is provided.

The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.